Image

Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy

Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy

Recruiting
Female
Phase N/A

Powered by AI

Overview

The current study is a multiple-arm, single blinded, and controlled randomized trial. It will be conducted in two gynecological endoscopy centers: • ElShatby University Hospital, a tertiary level hospital in Alexandria, Egypt. • Al-Madina Women Hospital, A specialized hospital of Obstetrics and Gynecology, Alexandria, Egypt. Patient selection: women with uterine leiomyomata and planning for laparoscopic myomectomy will be assessed for eligibility then will be enrolled in the trial according to the following inclusion and exclusion criteria, after providing a written informed consent of participation. Outcome variables of the study: The primary outcome is intraoperative blood loss and the change in postoperative hemoglobin. The secondary outcomes of this study are the operative time of performing uterine arteries occlusion and the postoperative ovarian reserve.

Description

The goal of this clinical trial is to evaluate the safety and impact on ovarian reserve of different techniques of bilateral uterine artery occlusion in women in the reproductive age group scheduled for laparoscopic myomectomy. The main question\[s\] it aims to answer \[is/are\]:Do the different techniques for laparoscopic uterine artery occlusion prior to myomectomy decrease the intraoperative blood loss and the postoperative hemoglobin? The investigator intends to compare three different techniques for laparoscopic uterine artery occlusion (clipping, temporary suture, and coagulation) versus control group (no occlusion of uterine arteries) to see the effect on intraoperative blood loss, postoperative hemoglobin, and impact on ovarian reserve. Participants will be randomly allocated into one of the following study arms: \ ARM 1: Will undergo temporary clipping of both uterine arteries before laparoscopic myomectomy (LAP-M). \ ARM 2: Will undergo temporary occlusion of both uterine arteries using the Shoe-lace suture technique before LAP-M. \ ARM 3: Will undergo permanent occlusion of both uterine arteries using bipolar coagulation before LAP-M. \ ARM 4 (Control group): Will undergo only LAP-M without occlusion of uterine arteries.

Eligibility

Inclusion Criteria:

  • women with uterine fibroids and complaining of either abnormal uterine bleeding, infertility, urinary or rectosigmoid pressure manifestations.
  • Fibroid size from 3 - 10 cm in diameter and with
  • a maximum number of 3 fibroids.

Exclusion Criteria:

  • contraindication to pneumoperitoneum and laparoscopy,
  • patients with BMI \> 30 kg/m2,
  • history of midline abdominal incisions,
  • women with history of prior ovarian surgery,
  • women with history of hormonal treatment for the last 3 months before surgery,
  • women who are not good candidate for myomectomy and who would benefit more from hysterectomy such as, women with multiple ≥ 4 leiomyomata, associated adenomyosis, recurrent fibroids after myomectomy.
  • suspected endometrial malignancy or suspected leiomyosarcoma features on ultrasound and/or MRI.
  • Submucous fibroids who will undergo hysteroscopic myomectomy beside the laparoscopic surgery.

Study details
    Uterine Fibroids (Leiomyoma)
    Myomectomy
    Myomectomy; Surgical Blood Loss

NCT07352761

Alexandria University

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.